The Immune Deficiency Foundation (IDF) applauded the introduction of legislation that would improve access to intravenous immunoglobulin (IVIG) for Medicare patients with immunodeficiency diseases.
Medicare does not pay for home IVIG treatment, but advocates for such coverage argue that it is safer to treat these patients in the home so they avoid exposure to infections in other health care settings and that home treatment will ultimately save Medicare money. The legislation (S 960 and HR 1845 [http://thomas.loc.gov]), introduced in May, would create a 3-year demonstration project in which Medicare would pay for in-home IVIG treatment to evaluate the benefits and costs of such care.
Mitka M. IVIG Legislation. JAMA. 2011;306(2):145. doi:10.1001/jama.2011.926